Faster regulation pledge is among China's five-year plan to boost drug industry
This article was originally published in SRA
Executive Summary
China's central government has released a five-year strategic plan for boosting the country's biopharmaceutical industry in which it pledges to adopt a series of polices such as shortening the new drug approval process and building a strong supervisory system for biologic drugs1.